title: Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults.
abstract: We analyzed our treatment results of 71 operated patients with cerebral glioblastoma treated by conventional external radiation therapy (mean dose 60.2 Gy) combined with radiosensitizing agents. More than 50% reduction of tumor volume was obtained in 20 patients (28.2%). A response rate of at least 40% was obtained in patients treated with combined ACNU-vincristine-nicardipine, ACNU-5FU-hydroxyurea, or cisplatin alone. The combination of ACNU and vincristine with or without nicardipine resulted in significantly longer survival. The median survival in this group was 101.1 weeks and the two-year survival rate was 45.9%; these results were significantly better than those achieved with other ACNU combinations or other combinations without ACNU. In the analysis of survival, factors correlated to longer survival were a patient age of younger than 45 years, wide resection of the tumor, a good postoperative performance status (KS > or = 70%), a radiation dose of 68-72 Gy, small postoperative tumor remnants (< 20 cm3), no visible tumor after radiation therapy, and the administration of adjuvant chemotherapy. Maximum resection of the tumor and localized irradiation with a dose of 70 Gy combined with ACNU and vincristine appears to be the most effective treatment at present.
authors: Department of Neurosurgery, Tokyo Metropolitan Komagome Hospital, Japan.
authors: M
authors: M
authors: Matsutani
authors: O
authors: O
authors: Nakamura
authors: M
authors: M
authors: Nakamura
authors: T
authors: T
authors: Nagashima
authors: A
authors: A
authors: Asai
authors: T
authors: T
authors: Fujimaki
authors: H
authors: H
authors: Tanaka
authors: K
authors: K
authors: Ueki
authors: Y
authors: Y
authors: Tanaka
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000008:administration & dosage; D015376:Nimustine / Q000008:administration & dosage; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D011838:Radiation-Sensitizing Agents; D015376:Nimustine; D014750:Vincristine; D009529:Nicardipine; D002945:Cisplatin